CSIMarket
 
Arcus Biosciences Inc   (RCUS)
Other Ticker:  
 
 
Price: $17.2200 $-1.76 -9.273%
Day's High: $18.98 Week Perf: -7.62 %
Day's Low: $ 17.16 30 Day Perf: 4.94 %
Volume (M): 1,003 52 Wk High: $ 25.47
Volume (M$): $ 17,265 52 Wk Avg: $18.09
Open: $18.92 52 Wk Low: $12.95



 Market Capitalization (Millions $) 1,274
 Shares Outstanding (Millions) 74
 Employees 21,164
 Revenues (TTM) (Millions $) 117
 Net Income (TTM) (Millions $) -307
 Cash Flow (TTM) (Millions $) -79
 Capital Exp. (TTM) (Millions $) 24

Arcus Biosciences Inc
Arcus Biosciences Inc (NASDAQ:RCUS) is a biotechnology company that focuses on discovering and developing innovative immunotherapies to treat cancer. The company is headquartered in Hayward, California and was founded in 2015 by a team of experienced biotech executives.

Arcus Biosciences' main objective is to develop new and innovative cancer treatments that will revolutionize the way we treat this disease. The company's highly skilled team of scientists is working diligently to develop and commercialize cancer immunotherapies based on the latest advances in immunology and genomic analysis.

The company's pipeline is focused on small molecule therapies and antibodies that target key immunomodulatory pathways, with the goal of enhancing the immune system's natural ability to identify and destroy cancer cells. This approach is designed to treat a wide range of cancers, including solid tumors and hematological malignancies.

Currently, Arcus Biosciences has three clinical-stage product candidates in development, each with the potential to address a significant unmet medical need in the oncology space. The company's lead product candidate, AB928, is a small molecule dual adenosine receptor antagonist that is being evaluated in combination with chemotherapy, radiation, and other checkpoint inhibitors. The goal of this combination therapy is to enhance the anti-tumor immune response, improve the efficacy of existing cancer treatments, and improve overall patient outcomes.

Another key product in the company's pipeline is AB154, an anti-TIGIT monoclonal antibody that is being developed as a next-generation checkpoint inhibitor. This therapy is designed to block the TIGIT pathway, which plays a critical role in suppressing the immune system's natural response to cancer. The company believes that AB154 has the potential to be a highly effective therapy in combination with other cancer treatments.

The third product candidate, AB680, is a small molecule inhibitor of CD73, an enzyme that is involved in the adenosine pathway. This therapy is being evaluated in combination with other checkpoint inhibitors with the goal of enhancing the immune response against tumors and improving overall patient outcomes.

As a relatively young company, Arcus Biosciences has already made significant progress in the development of new and innovative cancer therapies. In addition to its strong product pipeline, the company has established partnerships with several other leading biotech and pharmaceutical companies, including Gilead Sciences, Roche, and Taiho Pharmaceutical. These partnerships provide the company with substantial resources and support to continue advancing its research and development efforts.

Overall, Arcus Biosciences is a highly innovative and dynamic biotechnology company that is focused on developing new and effective cancer therapies. With a strong pipeline of product candidates and a talented team of scientists and researchers, the company is well-positioned to make a profound impact in the field of oncology and improve the lives of patients affected by this devastating disease.


   Company Address: 3928 Point Eden Way Hayward 94545 CA
   Company Phone Number: 694-6200   Stock Exchange / Ticker: NYSE RCUS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Transactions

Arcus Biosciences Empowers New Talent with Stock Options Amidst Steady Share Price Growth

Published Mon, Mar 11 2024 8:35 PM UTC


Hayward, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a leading biopharmaceutical company specializing in cancer treatments, has once again made headlines with the recent announcement of granting options to new employees. The Compensation Committee of the company's Board of Directors has awarded a total of 13,800 shares of Arcus Biosciences' common stock to four new te...

Stock Transactions

Arcus Biosciences Boosts Cancer Therapies Development with Employment Inducement Grants

Published Tue, Feb 27 2024 9:35 PM UTC

Arcus Biosciences Empowers Cancer Therapies Development with New Employment Inducement Grants
Arcus Biosciences, Inc. recently announced the granting of options to purchase a total of 17,600 shares of the company's common stock to four new employees. This move by the Compensation Committee of the Board of Directors aims to attract and retain top talent in their mission t...

Arcus Biosciences Inc

Arcus Biosciences Inc Faces Tough Fourth Quarter with Steep Decline in Revenue


By
As the financial results for the October to December 31, 2023 interval are released, it is clear that Arcus Biosciences Inc has faced significant challenges in maintaining revenue and profitability. Lower demand in the market has directly impacted the company's financial performance and resulted in larger losses.
During this financial period, Arcus Biosciences Inc experienced a loss per share of $-1.04, an increase from the loss of $-0.94 per share during the prior reporting period. Additionally, the company witnessed a decline in revenue, with figures dropping by -7.889% to $31.00 million, compared to $32.00 million in the previous year's corresponding period.

Stock Transactions

Arcus Biosciences Strengthens Cancer Research Team with New Inducement Grants to Support Innovative Therapies

Published Fri, Feb 9 2024 9:35 PM UTC

Arcus Biosciences Announces New Employment Inducement Grants to Support Cancer Research and Development
Hayward, Calif. - Arcus Biosciences, a leading global biopharmaceutical company dedicated to developing impactful molecules and combination therapies for individuals with cancer, has announced the granting of employment inducement grants to several new employees. Thes...

Financing Agreement

Gilead and Arcus Announce Amended Collaboration and Equity Investment: Accelerating Breakthrough Cancer Therapies

Published Mon, Jan 29 2024 10:00 PM UTC

Gilead Sciences, Inc. and Arcus Biosciences, Inc. have recently announced an amendment to their collaboration agreement, along with a significant equity investment by Gilead. The amendment and investment aim to accelerate the growth of the companies' joint development programs across multiple indications. In addition, Arcus Biosciences has granted stock options to new employ...






 

Arcus Biosciences Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Arcus Biosciences Inc does not provide revenue guidance.

Earnings Outlook
Arcus Biosciences Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com